Ironwood Pharmaceuticals (NASDAQ:IRWD) Cut to Buy at StockNews.com

StockNews.com lowered shares of Ironwood Pharmaceuticals (NASDAQ:IRWD - Free Report) from a strong-buy rating to a buy rating in a research report report published on Tuesday morning.

Several other equities research analysts have also recently weighed in on the stock. Wells Fargo & Company reduced their target price on shares of Ironwood Pharmaceuticals from $14.00 to $12.00 and set an "overweight" rating for the company in a research note on Friday, August 9th. Leerink Partnrs raised shares of Ironwood Pharmaceuticals to a "hold" rating in a research note on Monday, September 9th. Leerink Partners initiated coverage on shares of Ironwood Pharmaceuticals in a research report on Monday, September 9th. They issued a "market perform" rating and a $5.00 price objective on the stock. Craig Hallum lowered their price objective on shares of Ironwood Pharmaceuticals from $14.00 to $10.00 and set a "buy" rating on the stock in a research note on Friday, August 9th. Finally, Capital One Financial downgraded shares of Ironwood Pharmaceuticals from an "overweight" rating to an "equal weight" rating and reduced their target price for the stock from $12.00 to $4.00 in a report on Thursday, August 8th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Ironwood Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $10.40.

Ironwood Pharmaceuticals Trading Down 8.1 %

Shares of IRWD traded down $0.39 during midday trading on Tuesday, reaching $4.40. 1,582,312 shares of the company were exchanged, compared to its average volume of 2,934,806. Ironwood Pharmaceuticals has a 1-year low of $3.79 and a 1-year high of $15.70. The stock has a 50-day moving average price of $4.32 and a 200-day moving average price of $5.55. The company has a market cap of $702.06 million, a price-to-earnings ratio of -147.67 and a beta of 0.47.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.07). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The business had revenue of $91.60 million for the quarter, compared to analyst estimates of $91.22 million. During the same quarter in the prior year, the firm posted $0.12 earnings per share. The business's quarterly revenue was down 19.4% on a year-over-year basis. Equities research analysts anticipate that Ironwood Pharmaceuticals will post 0.26 earnings per share for the current year.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. CWM LLC raised its position in shares of Ironwood Pharmaceuticals by 55.1% in the 2nd quarter. CWM LLC now owns 6,600 shares of the biotechnology company's stock valued at $43,000 after purchasing an additional 2,345 shares during the last quarter. KBC Group NV raised its holdings in Ironwood Pharmaceuticals by 59.3% in the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company's stock valued at $35,000 after buying an additional 3,198 shares during the period. SG Americas Securities LLC acquired a new position in Ironwood Pharmaceuticals in the 1st quarter valued at about $91,000. GAMMA Investing LLC grew its position in shares of Ironwood Pharmaceuticals by 344.1% during the second quarter. GAMMA Investing LLC now owns 10,526 shares of the biotechnology company's stock worth $69,000 after buying an additional 8,156 shares in the last quarter. Finally, EntryPoint Capital LLC grew its position in shares of Ironwood Pharmaceuticals by 517.4% during the first quarter. EntryPoint Capital LLC now owns 10,589 shares of the biotechnology company's stock worth $92,000 after buying an additional 8,874 shares in the last quarter.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.